KRAS and colon adenocarcinoma: Contrarily, assessing patients with mid to late-stage COAD based on individual mutation statuses, such as KRAS and BRAF mutations, and MSI status offers more treatment opportunities17, However, the molecular level of COAD is very complex and relying on a single gene or factor to construct a predictive model would prove to be inefficient.